Stock events for Axsome Therapeutics, Inc. (AXSM)
Over the past six months, Axsome Therapeutics' stock price has been impacted by several key events. The company reported a wider-than-expected loss in Q4 2025, but total revenues surged 65% year-over-year. The Q3 2025 report was received positively, showing strong revenue growth from Auvelity and Sunosi. The launch of Symbravo for acute migraine in June 2025 has contributed to the company's revenue growth. The company dosed the first patient in its Phase 3 CLARITY trial for solriamfetol in major depressive disorder, and the FDA decision on AXS-05 for Alzheimer's disease agitation is expected by April 30, 2026. Several investment analysts have initiated or reaffirmed positive ratings for AXSM. The shares have soared 50.3% in the past six months, but there has also been notable insider selling activity.
Demand Seasonality affecting Axsome Therapeutics, Inc.’s stock price
Axsome Therapeutics' management has acknowledged that there can be potential seasonality effects impacting gross-to-net discounts for its products, specifically Auvelity and Sunosi, with expectations for these to rise in Q1. External factors such as the Change Healthcare cyberattack in Q1 2024 temporarily pressured gross-to-net and weekly prescriptions, although management reported a quick recovery.
Overview of Axsome Therapeutics, Inc.’s business
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. The company's primary focus is on addressing unmet medical needs in neurological and psychiatric conditions. Its major commercial products include Auvelity for major depressive disorder, Sunosi for excessive daytime sleepiness, and Symbravo for acute migraine. Axsome also has a diversified late-stage pipeline of product candidates, including AXS-05, AXS-12, AXS-14, AXS-17 and AZD7325.
AXSM’s Geographic footprint
Axsome Therapeutics is headquartered in New York, New York, United States. Its commercial operations and market presence are primarily focused on the United States, although it generates some royalty revenue from out-licensed territories for Sunosi.
AXSM Corporate Image Assessment
Axsome Therapeutics has generally maintained a positive brand reputation, driven by its strong commercial performance and pipeline advancements. Analysts have expressed optimism about the company's portfolio development and commercial efforts.
Ownership
Axsome Therapeutics has a diverse ownership structure, with a significant portion held by institutional investors. Key institutional shareholders include Vanguard Group Inc, BlackRock, Inc., and Price T Rowe Associates Inc /md/. Dr. Herriot Tabuteau, the founder, Chief Executive Officer, and Chairman, is the largest individual shareholder.
